The administration is drafting an executive order that would grant Office of Management and Budget Director Russell Vought absolute veto authority over every individual research grant awarded by the National Institutes of Health. The pending move follows a contentious West Wing showdown that reportedly sidelined NIH Director Jay Bhattacharya.
Friday reports from The Washington Post brought to light a contentious and high-stakes White House meeting in which the director of the National Institutes of Health (NIH), Jay Bhattacharya, attempted to fend off a concerted effort to place federal research funding decisions under strict political control. The initiative was spearheaded by Russell Vought, the head of the Office of Management and Budget (OMB), an agency that has systematically sought to limit, audit, and control federal research allocations. According to reporting from The Post, Bhattacharya ultimately ended up on the losing side of this policy battle, setting the stage for a dramatic structural shift in how biomedical science is funded in the United States.
This initial leak has since been independently confirmed and heavily expanded upon by prominent national news outlets, including The New York Times and Politico. It has now come to light that the administration is actively drafting an executive order that would hand Vought direct veto power over every single individual grant awarded by the NIH. Such a mechanism would effectively inject executive branch political oversight into tens of thousands of academic and clinical research awards annually, fundamentally altering the traditional peer-review ecosystem that has governed federal science funding for decades.
To understand the gravity of the pending executive order, one must examine the sheer scale of the institution targeted. The NIH stands as the largest single funder of biomedical research on the entire planet, anchored by a massive $47 billion budget that dwarfs that of the next 10 global research funders combined. Its capital, distributed largely through competitive grants to academic researchers at universities and medical centers across the nation, supports a vast spectrum of scientific inquiry - ranging from foundational basic biological research to complex clinical trials. This robust funding apparatus has historically served as the bedrock upon which the thriving American biotechnology and pharmaceutical industries have flourished.
Despite its unmatched output and economic footprint, the NIH has increasingly found itself in the crosshairs of executive policymakers. Vought has frequently expressed the viewpoint that the agency has historically funded a proliferation of what the administration characterizes as ideological or politically sensitive research. Immediately following President Trump's return to the Oval Office, the administration moved swiftly to terminate a broad range of existing grants focused on critical topics such as pandemic preparedness and public health disparities. Concurrently, the administration proposed a radical federal budget that would slash the NIH's operational capacity by nearly half.
That sweeping proposed cut was ultimately rejected by Congress, and the aggressive policy framework behind the initial wave of NIH grant terminations was subsequently voided by a federal court ruling. Undeterred by these legal and legislative setbacks, Vought pivoted strategy by proposing sweeping new grant funding rules designed to make political considerations core determinants in which scientific projects receive federal dollars. However, Congress promptly placed that regulatory rule on hold as well, creating a persistent institutional stalemate between executive ambitions and legislative oversight.
Apparently dissatisfied with merely blocking funding streams for entire fields of scientific study and frustrated by repeated congressional roadblocks, Vought engineered a new avenue to exert leverage over the NIH's grantmaking apparatus. According to detailed reports from Politico, Vought capitalized on a well-documented executive priority: the administration's ongoing financial and political friction with Harvard University. Early in the second term, the administration suspended all federal grant funding to a select group of elite universities, demanding substantial financial concessions in exchange for restoring funds and closing ongoing federal investigations.
When Harvard declined to acquiesce and successfully secured a favorable federal court ruling that restored its funding, public reports suggested a potential alternative settlement structure. In response, Trump immediately escalated demands, insisting upon a $1 billion payment from Harvard as a condition of any final resolution. During the high-level White House policy meeting, Vought reportedly pitched direct OMB control over NIH grant distribution as an effective alternative instrument to target institutional compliance at universities like Harvard. To his credit, NIH Director Bhattacharya strongly objected to the proposal during the proceedings.
Bhattacharya's willingness to push back against Vought's gambit was not treated by observers as a foregone conclusion. The NIH director has remained publicly vocal about his past frustrations regarding the handling of the COVID-19 pandemic, specifically believing that his alternative epidemiological strategies - such as allowing the virus to spread largely unchecked - were sidelined by the scientific establishment. Upon taking the helm at the NIH, Bhattacharya initially treated his post as a vehicle to address perceived historical grievances, cooperating in the termination of funding to politically sensitive research initiatives and frequently downplaying the controversial public health stances of his superior, Department of Health and Human Services Secretary Robert F. Kennedy, Jr. Given this alignment, many insiders anticipated he might back Vought's administrative maneuvers.
Nevertheless, with Bhattacharya reportedly losing the internal West House debate, all future NIH grants will now be subjected to rigorous approval by a newly formed administrative committee comprising both Vought and Bhattacharya. Under the proposed structure, unless this committee reaches unanimous agreement that a specific research grant should move forward, the funding will be formally rejected. Industry analysts and academic administrators are already sounding alarms regarding the practical implementation of such a system. During the Biden administration, the NIH successfully processed and funded over 64,000 grants annually. Given that Vought and Bhattacharya maintain extensive administrative duties running massive federal apparatuses, independent experts question how either official can realistically conduct a substantive, individualized evaluation of tens of thousands of complex scientific proposals without crippling the nation's biomedical research pipeline.
As Prime Minister enters his first parliamentary session, his administration faces a defining crisis over Palantir's sprawling £670m public sector contracts. Westminster insiders warn that deciding the fate of the US tech firm's NHS data agreements requires an immediate, high-stakes executive choice.
Major US television networks and print publications have suspended pooled coverage of President Donald Trump following the exclusion of CNN, Politico, and MS NOW. The affected media organisations have filed a federal lawsuit against the administration, while the White House defends its actions and launches an independent streaming initiative.
Once confident about expanding their Senate majority, Republican strategists are now scrambling to protect traditional strongholds as economic pressures mount across the Midwest. President Donald Trump's economic agenda faces intense scrutiny from voters, altering the trajectory of key legislative races.
